Search Results - jian-kang+jiang

5 Results Sort By:
Anti-Viral Compounds that Inhibit HIV Activity
Abstract: Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity.  Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses...
Published: 4/8/2024   |   Inventor(s): John Beutler, Jian-kang Jiang, Suhman Chung, Craig Thomas, Stuart LeGrice, Jennifer Wilson
Keywords(s): AIDS, HIV, ribonuclease H, RNase H, tropolone derivative, viral replication
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease
Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
This technology includes the identification and use of novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP), an autosomal-dominant rare disease that affects one person in every 1-2 million. FOP is characterized by malformation of the great (big) toes during embryonic development and by progressive heterotopic...
Published: 7/25/2024   |   Inventor(s): Jian-kang Jiang, Khalida Shamim, Philip Sanderson, Wei Zheng, Xiuli Huang, Gregory Tawa, Asaf Alimardanov, Arthur Lee, Junfeng Huang, Wenwei Huang
Keywords(s): ALK2, BMP, INHIBITING, Inhibitors, Methods, Novel, SIGNALING, VGXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Endocrinology, Application > Therapeutics, Application > Research Materials
Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance
This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical...
Published: 7/25/2024   |   Inventor(s): Jian-kang Jiang, Craig Thomas
Keywords(s): FTL3/IRAK, Inhibitors, MOLECULE, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Application > Research Materials
Pyruvate Kinase M2 Activators for the Treatment of Cancer
This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...
Published: 7/25/2024   |   Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas
Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials
Bi-Functional RGD Peptide and a Co-Signaling Mechanism to Promote Therapeutic Angiogenesis
Bi-Functional RGD Peptide to Promote Therapeutic Angiogenesis, Treat Ischemic Diseases Technology: While previous studies have focused on the identification of biological ligands to improve the functions of endothelial cells, MUSC and Clemson University researchers have combined modern bioinformatics and a newly established peptide functionalized...
Published: 3/23/2023   |   Inventor(s): Chung-Jen (James) Chou, Ying Mei, Jia Jia
Keywords(s):  
Category(s): BioPharma